-
Article
Open AccessExploring the genetics of lithium response in bipolar disorders
Lithium (Li) remains the treatment of choice for bipolar disorders (BP). Its mood-stabilizing effects help reduce the long-term burden of mania, depression and suicide risk in patients with BP. It also has bee...
-
Article
Open AccessLithium response in bipolar disorder is associated with focal adhesion and PI3K-Akt networks: a multi-omics replication study
Lithium is the gold standard treatment for bipolar disorder (BD). However, its mechanism of action is incompletely understood, and prediction of treatment outcomes is limited. In our previous multi-omics study...
-
Article
Open AccessAssociation of polygenic score and the involvement of cholinergic and glutamatergic pathways with lithium treatment response in patients with bipolar disorder
Lithium is regarded as the first-line treatment for bipolar disorder (BD), a severe and disabling mental health disorder that affects about 1% of the population worldwide. Nevertheless, lithium is not consiste...
-
Living Reference Work Entry In depth
Gene-Environment Interactions
An overview of gene-environment interactions (GxE) in psychiatric disorders is provided. GxE occur when genes and the environment work together to cause illness, and GxE research studies how risk for a specifi...
-
Article
Open AccessInvestigating the phenotypic and genetic associations between personality traits and suicidal behavior across major mental health diagnoses
Personality traits influence risk for suicidal behavior. We examined phenotype- and genotype-level associations between the Big Five personality traits and suicidal ideation and attempt in major depressive, bi...
-
Article
Open AccessCorrection: Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients
-
Article
Transcriptome-based polygenic score links depression-related corticolimbic gene expression changes to sex-specific brain morphology and depression risk
Studies in post-mortem human brain tissue have associated major depressive disorder (MDD) with cortical transcriptomic changes, whose potential in vivo impact remains unexplored. To address this translational ...
-
Article
Open AccessCombining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients
Lithium is the gold standard therapy for Bipolar Disorder (BD) but its effectiveness differs widely between individuals. The molecular mechanisms underlying treatment response heterogeneity are not well unders...
-
Article
Open AccessHLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders
Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is heterogeneous and relia...
-
Article
Correction: Investigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder
A Correction to this paper has been published: https://doi.org/10.1038/s41380-021-01063-8
-
Article
Open AccessInvestigating rare pathogenic/likely pathogenic exonic variation in bipolar disorder
Bipolar disorder (BD) is a serious mental illness with substantial common variant heritability. However, the role of rare coding variation in BD is not well established. We examined the protein-coding (exonic)...
-
Article
IN MEMORIAM: James C. Harris, MD (1940–2021)
-
Article
Association of polygenic score for major depression with response to lithium in patients with bipolar disorder
Lithium is a first-line medication for bipolar disorder (BD), but only one in three patients respond optimally to the drug. Since evidence shows a strong clinical and genetic overlap between depression and bip...
-
Article
Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology
Bipolar disorder is a heritable mental illness with complex etiology. We performed a genome-wide association study of 41,917 bipolar disorder cases and 371,549 controls of European ancestry, which identified 6...
-
Article
Minimal phenoty** yields genome-wide association signals of low specificity for major depression
Minimal phenoty** refers to the reliance on the use of a small number of self-reported items for disease case identification, increasingly used in genome-wide association studies (GWAS). Here we report diffe...
-
Article
Genome-wide association study identifies 30 loci associated with bipolar disorder
Bipolar disorder is a highly heritable psychiatric disorder. We performed a genome-wide association study (GWAS) including 20,352 cases and 31,358 controls of European descent, with follow-up analysis of 822 v...
-
Article
Open AccessGenome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals
Differential DNA methylation in the brain is associated with many psychiatric diseases, but access to brain tissues is essentially limited to postmortem samples. The use of surrogate tissues has become common ...
-
Chapter
Biobanking for ‘Omics’ in Psychiatry: Logistical and Ethical Aspects
Biobanks are highly specialized repositories for both biospecimens and associated demographic or clinical data. They have become a crucial component of big data research in all fields of medicine, in particula...
-
Article
Open AccessGenome-wide association study of seasonal affective disorder
Family and twin studies have shown a genetic component to seasonal affective disorder (SAD). A number of candidate gene studies have examined the role of variations within biologically relevant genes in SAD su...
-
Article
Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression
Major depressive disorder (MDD) is a common illness accompanied by considerable morbidity, mortality, costs, and heightened risk of suicide. We conducted a genome-wide association meta-analysis based in 135,45...
